|
gptkbp:instanceOf
|
gptkb:drug
biologic medication
|
|
gptkbp:administeredBy
|
intravenous infusion
|
|
gptkbp:approvalYear
|
1998
|
|
gptkbp:approvedBy
|
gptkb:United_States
gptkb:FDA
|
|
gptkbp:ATCCode
|
L04AB02
|
|
gptkbp:biosimilar
|
gptkb:Inflectra
gptkb:Ixifi
gptkb:Renflexis
|
|
gptkbp:contraindication
|
heart failure
active infections
|
|
gptkbp:cost
|
high
|
|
gptkbp:developedBy
|
gptkb:Centocor
|
|
gptkbp:form
|
lyophilized powder for solution
|
|
gptkbp:genericName
|
gptkb:infliximab
|
|
gptkbp:halfLife
|
8-10 days
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Remicade
|
|
gptkbp:indication
|
gptkb:psoriatic_arthritis
moderate to severe rheumatoid arthritis
moderate to severe ulcerative colitis
ankylosing spondylitis
moderate to severe Crohn's disease
plaque psoriasis
|
|
gptkbp:legalStatus
|
prescription only
|
|
gptkbp:manufacturer
|
gptkb:Janssen_Biotech
|
|
gptkbp:marketedIn
|
gptkb:Australia
gptkb:Canada
gptkb:European_Union
gptkb:Japan
gptkb:United_States
|
|
gptkbp:mechanismOfAction
|
TNF-alpha inhibitor
|
|
gptkbp:molecularWeight
|
149 kDa
|
|
gptkbp:patentExpired
|
2018 (US)
|
|
gptkbp:pregnancyCategory
|
B
|
|
gptkbp:prescriptionRequired
|
yes
|
|
gptkbp:product
|
gptkb:monoclonal_antibody
|
|
gptkbp:routeOfAdministration
|
intravenous
|
|
gptkbp:sideEffect
|
abdominal pain
headache
infections
infusion reactions
|
|
gptkbp:storage
|
2-8°C
|
|
gptkbp:target
|
gptkb:tumor_necrosis_factor_alpha
|
|
gptkbp:usedFor
|
gptkb:Crohn's_disease
gptkb:psoriatic_arthritis
ulcerative colitis
rheumatoid arthritis
ankylosing spondylitis
plaque psoriasis
|
|
gptkbp:WHOModelListOfEssentialMedicines
|
yes
|
|
gptkbp:bfsParent
|
gptkb:Merck_&_Co.
|
|
gptkbp:bfsLayer
|
4
|